HMG vs Letrozole
A side-by-side research comparison of HMG and Letrozole across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | HMG | Letrozole |
|---|---|---|
| Full name | Human Menopausal Gonadotropin (Menotropins) | Letrozole (Femara) |
| Category | Fertility | Fertility |
| Status | FDA Approved | FDA Approved (off-label fertility) |
| Mechanism | FSH component directly stimulates Sertoli cells to support spermatogenesis in men, and granulosa cells for follicle growth in women. LH component stimulates Leydig cells (testosterone) in men and theca cells (androgen precursors) in women. | Reversibly inhibits aromatase (CYP19A1), blocking conversion of androgens to estrogens. In women, transient estrogen reduction triggers hypothalamic GnRH release for FSH surge. In men, reduces estradiol while maintaining testosterone. |
| Molecular weight | FSH: ~35,000 Da; LH: ~30,000 Da | 285.30 Da |
| Half-life | FSH: ~37 hours; LH: ~20 hours | ~2 days |
| Bioavailability | ~100% (intramuscular/subcutaneous) | ~100% oral |
| Typical dose | 75-150 IU | 2.5-7.5 mg (women, day 3-7); 0.5-2.5 mg (men, 2-3x/week) |
| Frequency | 3x weekly (men) or daily (women, stimulation) | Cyclic (women) or 2-3x weekly (men) |
| Route | Intramuscular or subcutaneous injection | Oral tablet |
HMG reported benefits
- Spermatogenesis restoration
- Ovarian follicle stimulation
- Fertility recovery after TRT
- Improved sperm count and motility
- IVF protocol support
Letrozole reported benefits
- Ovulation induction (PCOS)
- Higher live birth rates than clomiphene
- No anti-estrogenic endometrial thinning
- Estradiol control in men
- Lower multiple pregnancy rate
Related comparisons
Research and educational reference only. Not medical advice.